Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phenobarbital→

Phenobarbital Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-06-6
Molecular formula
C12H12N2O3
Molecular weight
232.23 g/mol
Drug class
Barbituratelong-acting anticonvulsant and sedative-hypnotic
Mechanism of action
Enhances GABAA receptor-mediated inhibitory neurotransmission by prolonging the duration of chloride-channel opening, hyperpolarising neurons and reducing neuronal excitability. At higher concentrations it can also directly activate GABAA receptors.
Indications / reported uses
  • Treatment of selected seizure disorders, including focal and generalised tonic-clonic seizures.
  • Sedative or anaesthetic adjunct use in selected clinical settings, depending on formulation and local authorisation.

Sources: https://www.ncbi.nlm.nih.gov/books/NBK532277/ · https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=phenobarbital

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Phenobarbital Environmental Risk Assessment (ERA) (the Phenobarbital ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.